Show simple item record

dc.contributor.authorHorsch, D
dc.contributor.authorGarcia-Carbonero, R
dc.contributor.authorValle, Juan W
dc.contributor.authorPerros, P
dc.contributor.authorWelin, S
dc.contributor.authorKeeber, L
dc.contributor.authorHouchard, A
dc.contributor.authorLapuerta, P
dc.date.accessioned2019-04-29T09:48:51Z
dc.date.available2019-04-29T09:48:51Z
dc.date.issued2018en
dc.identifier.citationH�rsch D, Garcia-Carbonero R, Valle JW, Perros P, Welin S, Keeber L, et al. 1314P Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies. Annals of Oncology. 2018;29(suppl_8).en
dc.identifier.pmidNo PMIDen
dc.identifier.doi10.1093/annonc/mdy293.007en
dc.identifier.urihttp://hdl.handle.net/10541/621720
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy293.007en
dc.titleEfficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studiesen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Gastroenterology/Endocrinology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germanyen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T12:06:35Z


Files in this item

Thumbnail
Name:
561572.pdf
Size:
105.5Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record